Wash U Study Highlights Power of Sequencing Patient Tumors in Breast Cancer Clinical Trial

The researchers found that tumors from patients resistant to treatment were more highly mutated than those who responded. In the therapy-responsive group, they also found a druggable pathway that was highly mutated, suggesting that a drug combination could be an effective treatment for those patients.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.